



Universiteit  
Leiden  
The Netherlands

## Tailoring adjuvant therapy for hormone receptor-positive breast cancer

Blok, E.J.

### Citation

Blok, E. J. (2018, May 31). *Tailoring adjuvant therapy for hormone receptor-positive breast cancer*. Retrieved from <https://hdl.handle.net/1887/63078>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/63078>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The following handle holds various files of this Leiden University dissertation:  
<http://hdl.handle.net/1887/63078>

**Author:** Blok, E.J.

**Title:** Tailoring adjuvant therapy for hormone receptor-positive breast cancer

**Issue Date:** 2018-05-31



# Tailoring Adjuvant Therapy for Hormone Receptor- Positive Breast Cancer

Erik J. Blok



Tailoring adjuvant therapy for hormone  
receptor-positive early breast cancer

Erik J. Blok

Lay-out: Ferdinand van Nispen, [my-thesis.nl](http://my-thesis.nl)

Cover design: Dorijn Otto

Printed by: GVO drukkers & vormgevers

Tailoring adjuvant therapy for hormone receptor-positive early breast cancer

Thesis, Leiden University Medical Center, 2018

© Erik J. Blok, The Netherlands, 2018

ISBN: 978-94-6332-334-5

Printing of this thesis was financially supported by: afdeling Medische Oncologie (LUMC), Agendia, Chipsoft, Pfizer and Philips Research

# Tailoring adjuvant therapy for hormone receptor-positive early breast cancer

## **Proefschrift**

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,  
volgens besluit van het College voor Promoties  
te verdedigen op donderdag 31 mei 2018 klokke 13:45 uur.

**door**

Erik Jan Blok

Geboren te Papendrecht

in 1989

Promotor: Prof. dr. C.J.H. van de Velde

Copromotores: Dr. J.R. Kroep  
Dr. P.J.K. Kuppen

Promotiecommissie: Prof. dr. V.T.H.B.M. Smit  
Prof. dr. S.C. Linn (NKI/AvL)  
Prof. dr. ir. J.J.M. van der Hoeven (Radboud UMC)



Pap, deze is voor jou

Leo Blok  
27/8/1959 – 22/10/2015

# Contents

Chapter 1	General Introduction	9
Part 1	<b>Clinical use of extended endocrine therapy</b>	19
Chapter 2	Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence	21
Chapter 3	Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05)	39
Chapter 4	Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer	59
Chapter 5	Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer	75

<b>Part 2</b>	<b>Biomarker-based tailoring of adjuvant therapy</b>	93
<b>Chapter 6</b>	ER pathway activity as a predictive marker during neo-adjuvant endocrine therapy in early breast cancer; Results of the TEAM IIA trial	95
<b>Chapter 7</b>	Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer	117
<b>Chapter 8</b>	Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer	135
<b>Chapter 9</b>	Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe	157
<b>Chapter 10</b>	Letter to the editor: 70-Gene Signature in Early-Stage Breast Cancer	197
<b>Chapter 11</b>	General discussion	201
<b>Part 3</b>	<b>Appendices:</b>	213
	Nederlandse samenvatting	216
	List of publications	223
	List of co-authors	225
	Curriculum Vitae	226
	Dankwoord	227

